<DOC>
	<DOC>NCT01635764</DOC>
	<brief_summary>Hidradenitis Suppurativa is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring. This Study is an open-label extension study available to subjects who participated in a prior adalimumab study who meet all the inclusion and none of the exclusion criteria. The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe HS.</brief_summary>
	<brief_title>Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa</brief_title>
	<detailed_description>The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe HS. The clinical trial identifier is PIONEER (OPEN-LABEL EXTENSION).</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects who previously participated in a prior Phase 3 Abbott HS study and: 1. Completed the study; or 2. Experienced a loss of response (LOR); or 3. Experienced Worsening or Absence of Improvement Prior treatment with any other antiTNF therapy (e.g., infliximab, etanercept), or participation in an adalimumab trial other than a prior Phase 3 Abbott HS study. Subject received any oral antibiotic treatment for HS within 28 days prior to the Baseline visit, except for antibiotics permitted in a prior Phase 3 Abbott HS study. Subject received oral concomitant analgesics (including opioids) for HSrelated pain within 14 days prior to the Baseline visit, except for permitted analgesics taken in the prior Phase 3 Abbott HS study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hidradenitis suppurativa</keyword>
	<keyword>adalimumab</keyword>
	<keyword>open-label</keyword>
	<keyword>HS</keyword>
	<keyword>acne inversa</keyword>
	<keyword>PIONEER (OPEN-LABEL EXTENSION)</keyword>
	<keyword>acne</keyword>
	<keyword>tumor necrosis factor</keyword>
	<keyword>boil</keyword>
</DOC>